pDONR223-AKT1 Citations (4)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-AKT1

Articles
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gossele U, Koch B, Faber K, Genze F, Schrader M, Kestler HA, Dohner H, Chiosis G, Glimm H, Frohling S, Scholl C. J Exp Med. 2012 Apr 9;209(4):697-711. doi: 10.1084/jem.20111910. Epub 2012 Mar 26. PubMed
HSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization. Azoitei N, Diepold K, Brunner C, Rouhi A, Genze F, Becher A, Kestler H, van Lint J, Chiosis G, Koren J 3rd, Frohling S, Scholl C, Seufferlein T. Cancer Res. 2014 Dec 1;74(23):7125-36. doi: 10.1158/0008-5472.CAN-14-1017. Epub 2014 Oct 8. PubMed
DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells. Yang Y, Bardeleben C, Frost P, Hoang B, Shi Y, Finn R, Gera J, Lichtenstein A. Genes Cancer. 2014 Nov;5(11-12):407-19. PubMed
SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism. Hoang B, Shi Y, Frost PJ, Mysore V, Bardeleben C, Lichtenstein A. Mol Cancer Res. 2016 Apr;14(4):397-407. doi: 10.1158/1541-7786.MCR-15-0422. Epub 2016 Feb 11. PubMed

If you have published an article using this material, please email us at to have your article added to this page.